TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) will issue its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

TRACON Pharmaceuticals (NASDAQ:TCON) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.12. The company had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $0.81 million. TRACON Pharmaceuticals had a negative return on equity of 119.93% and a negative net margin of 963.11%. On average, analysts expect TRACON Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) opened at $2.90 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.57 and a quick ratio of 3.57.

Separately, Zacks Investment Research lowered shares of TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th.

TRADEMARK VIOLATION NOTICE: “TRACON Pharmaceuticals, Inc. (TCON) Scheduled to Post Quarterly Earnings on Monday” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/tracon-pharmaceuticals-inc-tcon-scheduled-to-post-quarterly-earnings-on-monday/1677039.html.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Earnings History for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.